4DMedical Limited
FDMDF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.08 | -0.04 | 0.30 |
| FCF Yield | -94.30% | -4.18% | -8.57% | -5.18% |
| EV / EBITDA | -0.81 | -14.63 | -7.16 | -26.20 |
| Quality | ||||
| ROIC | -21.54% | -15.88% | -23.05% | -18.09% |
| Gross Margin | 90.67% | 93.49% | -525.58% | -1,616.77% |
| Cash Conversion Ratio | 1.86 | 0.74 | 0.79 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | 87.85% | 49.07% | 32.39% | 3.23% |
| Free Cash Flow Growth | -43.61% | 10.18% | -2.73% | 15.49% |
| Safety | ||||
| Net Debt / EBITDA | 0.11 | 0.50 | 1.15 | 4.48 |
| Interest Coverage | -691.68 | 0.00 | -179.79 | -185.83 |
| Efficiency | ||||
| Inventory Turnover | 0.30 | 0.18 | 18.67 | 12.23 |
| Cash Conversion Cycle | -270.37 | -2,098.62 | 32.90 | 1,149.43 |